Last reviewed 2026-04-23 · How we verify

AB1010

AB1010 is a small molecule that targets the PI3K pathway.

AB1010 is a small molecule that targets the PI3K pathway. Used for Metastatic breast cancer.

At a glance

Mechanism of action

AB1010 works by inhibiting the PI3K enzyme, which is involved in cell signaling pathways. This inhibition can lead to the reduction of cancer cell growth and proliferation.

Approved indications

• Metastatic breast cancer

Common side effects

• Diarrhea
• Nausea
• Fatigue

Key clinical trials

• Masitinib in Patients With Mild Alzheimer's Disease (PHASE3)
• Efficacy and Safety of Masitinib in Combination With SoC Versus Placebo in the Treatment of ALS Patients (PHASE3)
• Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients (PHASE3)
• Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis (PHASE3)
• Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS) (PHASE2, PHASE3)
• Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer (PHASE3)
• Masitinib in Patients With Mild to Moderate Alzheimer's Disease (PHASE3)
• Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• AB1010 CI brief — competitive landscape report
• AB1010 updates RSS · CI watch RSS
• AB Science portfolio CI